BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 194 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $234,546 | +2.1% | 33,128 | +1.6% | 0.00% | 0.0% |
| Q2 2023 | $229,659 | +27.6% | 32,622 | +128.4% | 0.00% | 0.0% |
| Q3 2022 | $180,000 | -42.9% | 14,285 | -53.8% | 0.00% | 0.0% |
| Q1 2021 | $315,000 | -76.3% | 30,950 | -82.6% | 0.00% | -83.3% |
| Q4 2020 | $1,329,000 | +198.7% | 178,325 | +37.7% | 0.01% | +200.0% |
| Q3 2020 | $445,000 | +12.7% | 129,470 | +56.1% | 0.00% | 0.0% |
| Q2 2020 | $395,000 | +66.0% | 82,955 | -30.4% | 0.00% | 0.0% |
| Q1 2020 | $238,000 | -22.5% | 119,180 | +33.8% | 0.00% | 0.0% |
| Q4 2019 | $307,000 | +132.6% | 89,050 | +253.8% | 0.00% | +100.0% |
| Q3 2017 | $132,000 | +13.8% | 25,170 | +95.7% | 0.00% | 0.0% |
| Q1 2015 | $116,000 | – | 12,860 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |